Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MARS1 | P56192 | 7/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.36 |
| ▸ | ALPL | P05186 | 1/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.36 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.35 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.35 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL868834 | 0.90 | DPP4 (0.39) | MARS1NPC1RAB9ATGFBR1ALPL | |
| SCHEMBL1913168 | 0.87 | MAPT (0.44) | NPC1RAB9APOLBTGFBR1DPP4 | |
| SCHEMBL337927 | 0.82 | IDO1 (0.39) | NPC1MEN1POLBKMT2A | |
| SCHEMBL1913155 | 0.82 | CRHR1 (0.36) | NPC1MEN1KMT2ADPP4DPP8 | |
| SCHEMBL1913174 | 0.82 | DPP4 (0.38) | MEN1KMT2ADPP4DPP8 | |
| SCHEMBL340135 | 0.76 | DPP4 (0.42) | ALPLSLC2A1DPP4DPP8 | |
| SCHEMBL339827 | 0.75 | DPP4 (0.43) | NPC1RAB9AMEN1KMT2AALPL | |
| SCHEMBL339904 | 0.75 | ALPL (0.46) | NPC1RAB9AMEN1POLBKMT2A | |
| SCHEMBL1913178 | 0.75 | PAK3 (0.41) | CYP2C9DPP4 | |
| SCHEMBL1913165 | 0.75 | CRHR1 (0.42) | NPC1RAB9AMEN1CYP2C9KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120077787-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077787-A1 | ORGANIC COMPOUNDS | OAT, GPR119, OTC | MARS1 2908/4885NPC1 605/4885RAB9A 4708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.